$0.24
▲ +1.7% Today
as of Jul 22, 16:56 ET
Last 30 days
Recent Press Releases & News
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Overview
52-week range
$0.43
$5.14
0% of range
Avg surprise (last 2)
+8.7%
Avg reaction (last 1)
+0.8%
100% positive
Latest IV / EM
1045%
EM ±239.1% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed Dec 31, 2025 | Dec 2025 | $-0.45 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.54 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.47 | $-0.47 | 0.0% | — | — | earnings |
| Tue Jun 17, 2025 | Mar/2025 | $-0.43 | $-0.52 | +17.3% | — | +0.8% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.46 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.35 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.66 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.94 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.29 | -$0.47 | +38.3% |
Financials
Income statement (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-20M | $-20M | $-16M | — | $-15M | $-14M | $-12M | — |
| Net income | $-19M | $-19M | $-15M | — | $-14M | $-13M | $-11M | — |
| EPS (diluted) | $-0.45 | $-0.54 | $-0.47 | — | $-0.46 | $-0.42 | $-0.35 | — |
Balance sheet (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $47M | $63M | $49M | $67M | $75M | $84M | $103M | $119M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $63M | $79M | $67M | $82M | $90M | $100M | $111M | $121M |
| Total assets | $65M | $81M | $69M | $84M | $92M | $102M | $114M | $124M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $14M | $15M | $12M | $14M | $11M | $10M | $9M | $9M |
| Total equity | $51M | $66M | $57M | $70M | $81M | $93M | $105M | $114M |